source
- Roche reports updated eye drug data and FDA filing acceptance, targets July 2027 decisionRoche Genentech has presented new data from its eye disease trials, a year after a mixed Phase 3 readout, and noted that the FDA has accepted its filing for vamikibart with a decision slated for Ju…
- Bristol Myers reports two Phase 3 successes for fibrosis and RayzeBio drugBristol Myers Squibb announced Monday that two of its late-stage trials have met primary endpoints. The first trial involved its fibrosis program, where the experimental therapy demonstrated the e…